A composition comprising a compound selected from the group comprising glutamine, pharmaceutically acceptable salts thereof, and combinations thereof, the composition being suitable for use in a method of treatment or prevention of a condition or disorder associated with a decrease or lack of release of intestinal hormone secreted from L cells, selecting the condition or disorder among diabetes, metabolic syndrome, hypertriglyceridemia, obesity and polycystic ovary syndrome, said method comprising administering a sufficient composition to an individual to induce the release of an intestinal hormone from the L cells in the colon, in which the composition is formulated so that the compound is not released neither in the stomach nor in the gastrointestinal tract, in which either: (a) said composition is formulated in a drug delivery system directed to the colon or formulated for rec administration such, in which the compound delivery system is selected from covalent bonding compositions, polymer coating compositions, matrix embedded compositions, time-release compositions, redox-sensitive polymer compositions, bioadhesive compositions, microparticle coating compositions , osmotic delivery compositions, compositions containing polysaccharides, compositions in which the compound is coupled with a soluble or biodegradable polymer and retention enemas； or (b) said composition is formulated in a drug delivery system targeting the colon, the delivery system targeting the colon, a matrix system within the matrix, which is a controlled release formulation of a first hydrophilic matrix that it comprises a lipophilic phase and an amphiphilic phase, in which the lipophilic phase and the amphiphilic phase are in a second matrix combined and said second matrix is dispersed in the first hydrophilic matrix, and in which the compound is at least partially incorporated into the amphiphilic phaseUna composición que comprende un compuesto seleccionado del grupo que comprende glutamina, s
